Dexilant (dexlansoprazole) is a new-generation proton pump inhibitor (PPI) that is licensed to treat gastroesophageal reflux disease (GERD) in children and adults. While PPIs are the mainstay of treatment in acid-related conditions, dexlansoprazole has a unique dual-release formulation that sets it apart from its contemporaries. It produces a peak plasma level at about one hour after administration. Its second component then produces a second peak after four hours, further extending its therapeutic effects.
In the early 1990s, a new class of drugs called proton pump inhibitors entered the US market and revolutionized the treatment of acid peptic disorders. Up to this day, they are considered the best therapeutic option for GERD. Not surprisingly, they are also the first-line treatment for non-erosive reflex disease (NERD), functional dyspepsia, Zollinger-Ellison syndrome, peptic ulcer disease, and prevention of nonsteroidal anti-inflammatory drugs (NSAID) associated ulc ...
Diabetes mellitus, an inadequate insulin response to the sugar in the system, only demonstrates how miraculous the working system is when not compromised. When this system is faulty, however, a person with diabetes must take on the jobs that his or her body won’t do; these include:
Determine the amount of sugar in the bloodstream;
Release insulin to metabolize that sugar into the cells for energy;
Fine-tune the sugar levels within a tight range to maintain alertness and even consciousness without overshooting, which can result in loss of consciousness, or undershooting, which can result in tissue damage.
It’s a lot easier when the sensitive cells in the pancreas do most of the work in the background. Unfortunately, this is not the case with diabetes.
The mechanics of stepping in to do the job the pancreas won’t do
To accomplish a semblance of normality, a diabetic person must determine his or her actual blood sugar based on a “sliding ...